Market Overview

Recap: NeoGenomics Q3 Earnings



Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share fell 14.29% year over year to $0.06, which beat the estimate of $0.04.

Revenue of $125,444,000 higher by 19.84% year over year, which missed the estimate of $126,230,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

NeoGenomics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Oct 27, 2020

Time: 08:30 AM

ET Webcast URL:


52-week high: $44.58

Company's 52-week low was at $19.67

Price action over last quarter: Up 11.78%

Company Description

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.


Related Articles (NEO)

View Comments and Join the Discussion!

Posted-In: Earnings News